In an era of cancer immunotherapies, the recent introduction of neoantigen cancer vaccines has garnered new hope in the medical community, owing to their ability to induce the body’s natural defenses against abnormal malignancies. Cancers often target antigens present on normal cells in addition to cancerous cells, which further makes the patient’s body vulnerable to attacks in the wrong places by the current mainstays of immunotherapies. However, this undesirable phenomenon provides an opportunity for neoantigen cancer vaccines to step in and fill up the potential treatment gaps by selectively targeting cancer-associated antigens.

Neoantigen targeting therapeutics basically works on the strategy of immune system stimulation by the selective expansion of tumor-unique antigens targeted T-cells, which ultimately results in a strong immune response. The advancements in molecular profiling, neoantigen prediction, and next-generation gene sequencing technologies have now enabled neovaccines to couple with checkpoint inhibitors for a more potent and multiplexed treatment response. Several pharmaceutical giants and small-scale biotechnology companies currently have their products pipelined for launches in the market. Vaccines by most of these companies are in the initial stages of clinical development or are in the late (Phase III) stage of clinical development.

According to Nitish Singh, Lead Analyst at Our Research Team, “North America is expected to be a leading contributor in the global neoantigen cancer vaccine market and is anticipated to contribute approximately 55.50% of the projected global market value in 2024. This region is expected to grow significantly during the forecast period 2024-2031 and will continue to dominate the global market in 2031. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. The Europe region is also expected to contribute a significant share of 35.50% to the global market in 2024.”

This report is a meticulous compilation of research on more than 30 players in the market ecosystem. It draws upon insights from in-depth interviews with the key opinion leaders of leading companies, market participants, and vendors. The report also comprises 15 detailed company profiles, including several key players such as Moderna Therapeutics, Medigene, Neon Therapeutics, Advaxis, Agenus, F. Hoffmann-La Roche Ltd, AstraZeneca, Immunovative Therapies, and Nouscom.

Key Questions Answered in the Report:

• What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccines market?
• What are the underlying structures resulting in emerging trends within the global neoantigen cancer vaccines market?
• What key development strategies are implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for neoantigen cancer vaccines?
• How each segment of the market is expected to grow during the forecast period 2024-2031, and what is the estimated revenue to be generated by each of the segments on the basis of:
o Product Type (Personalized and Off-the-Shelf),
o Type of Neovaccine (Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine)
o Line of Therapy (First Line, Second Line, and Later Lines)
o Region, including North America, Europe, Asia-Pacific and Middle East
• Who are the leading players with significant offerings to the global neoantigen cancer vaccines market? What is the expected market dominance for each of these leading players?
• Which companies are anticipated to be highly disruptive in the future and why?
• What are the current treatment gaps, and how neovaccines are expected to fill these gaps?
• What are the unmet needs in the global neoantigen cancer vaccine market?
Buy the report: Global Neoantigen Cancer Vaccine Market: Focus on Approach, Line of Therapy, Type, Application, Treatment Strategy, and Country-Wise Analysis – Analysis and Forecast, 2024-2031
[contact-form-7]

The post CRI Report: neoantigen cancer vaccine market is expected to grow at a CAGR of 77.73% first appeared on CRI Report.

The global neoantigen cancer vaccine industry analysis projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031. The neoantigen cancer vaccine market is expected to generate $35.5 million in revenue in 2024, owing to the expected launch of the first neoantigen vaccine, DC vaccine in the market.

The neoantigen cancer vaccine market growth has been primarily attributed to major drivers in this market, such as rising prevalence of cancers, increasing adoption of personalized medicine to tailor patient’s treatment on an individual level, and significant external funding for executing research and development exercises. However, significant challenges are restraining the market growth. These challenges include the expected higher cost of personalized cancer vaccines, hurdles in clinical development, and payer uncertainty and outcome-based pricing.

Details in the report : Global Neoantigen Cancer Vaccine Market: Focus on Approach, Line of Therapy, Type, Application, Treatment Strategy, and Country-Wise Analysis – Analysis and Forecast, 2024-2031

What are Neoantigen cancer vaccines?

Neoantigen cancer vaccines are generally considered tumor-specific vaccines that are based on neoantigens being identified from an individual and further delivered via cell, protein, or nucleic acid-based platform with the utter aim of imparting a strong antitumor response. The neoantigen cancer vaccines are further segmented into personalized and off-the-shelf neovaccines based on the target neoantigen.

Neoantigen Cancer Vaccine in Cancer Immunotherapy

What are Growth Drivers of the Neoantigen cancer vaccines market?

• Increasing Global Prevalence of Cancer
• Increase in Adoption of Personalized Medicine to Tailor Patient’s Treatment on an Individual Level
• Significant External Funding for Executing Research and Development Exercise

What are Market Challenges for market players?

• Higher Cost of Personalized Cancer Vaccines
• Hurdles in Clinical Development and Optimization Process
• Uncertain Reimbursement Scenario
• Payer Uncertainty and Outcome-Based Pricing
• High Capital Requirement Hampering the Expansion of Global Reach

Who are top players in the Neoantigen cancer vaccines market?

Moderna Therapeutics

Website: www.modernatx.com

Moderna Therapeutics is a Cambridge, Massachusetts-based biotechnology company that specializes in messenger RNA (mRNA) based-drug discovery and development.

The company primarily caters to immuno-oncology, rare disease, and infectious disease therapy areas and currently holds three emerging neo-antigen vaccine candidates with respect to the global neoantigen cancer vaccine market.

It utilizes proprietary mRNA technology to develop novel mRNA-based neoantigen cancer vaccines, which are further delivered intramuscularly by lipid nanoparticles-based delivery vehicles.

Moderna’s expected stature as an emerging market player is primarily attributed to the portfolio of two personalized (mRNA-4650 and mRNA-4157) and one off-the-shelf neoantigen vaccine (mRNA-5671) in its pipeline. These vaccines, if approved, can generate phenomenal sales for the company.

F. Hoffmann-La Roche Ltd
AstraZeneca plc
Agenus
OSE Immunotherapeutics
Advaxis
Medigene
Neon Therapeutics
Genocea Biosciences
Immunovative Therapies
Gritstone Oncology
Nouscom
NantBioScience
Immunovaccine
BioLineRx
Geneos Therapeutics

How to get more details of the market?

Buy the report: Global Neoantigen Cancer Vaccine Market: Focus on Approach, Line of Therapy, Type, Application, Treatment Strategy, and Country-Wise Analysis – Analysis and Forecast, 2024-2031

Key Questions Answered in this Report:

• What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccines market?
• What are the underlying structures resulting in emerging trends within the global neoantigen cancer vaccines market?
• What key development strategies are implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for neoantigen cancer vaccines?
• How each segment of the market is expected to grow during the forecast period 2024-2031, and what is the estimated revenue to be generated by each of the segments on the basis of:
o Product Type (Personalized and Off-the-Shelf),
o Type of Neovaccine (Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine)
o Line of Therapy (First Line, Second Line, and Later Lines)
o Region, including North America, Europe, Asia-Pacific and Middle East
• Who are the leading players with significant offerings to the global neoantigen cancer vaccines market? What is the expected market dominance for each of these leading players?
• Which companies are anticipated to be highly disruptive in the future and why?
• What are the current treatment gaps, and how neovaccines are expected to fill these gaps?
• What are the unmet needs in the global neoantigen cancer vaccine market?

The post Global Neoantigen cancer vaccines market expected to generate $35.5 million in revenue in 2024 first appeared on CRI Report.